Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brenda Latowsky

Procedural Dermatology Scottsdale, AZ Medical Doctor

NPI 1306010467 CMS profile 13863

20201 N Scottsdale Healthcare Dr, Suite 260, Scottsdale, AZ 85255

Open in the dashboard

General payments

$152,286

572 records reported · program years 2019–2025

Research payments

$19,029

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,506,089 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Brenda Latowsky of Scottsdale, AZ is reported in the CMS Open Payments database as having received $152,286 across 572 general payments and $19,029 in research payments paid to them. Separately, studies naming them as principal investigator received $3,506,089 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36,783 137
2024 General $24,149 129
2024 Research $1,800 1
2023 General $23,178 100
2022 General $53,128 71
2022 Research $136 1
2021 General $5,278 44
2021 Research $200 1
2020 General $7,321 43
2020 Research $3,549 1
2019 General $2,449 48
2019 Research $13,344 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brenda Latowsky
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Brenda Latowsky were reported at $36,783. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Brenda Latowsky Procedural Dermatology median Middle half National median
2019 $2,449 $454 $152–$1,260 $163
2020 $7,321 $243 $90–$835 $114
2021 $5,278 $337 $102–$1,128 $132
2022 $53,128 $443 $119–$1,654 $149
2023 $23,178 $583 $137–$1,838 $160
2024 $24,149 $611 $132–$1,835 $164
2025 $36,783 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $62,204 202 payments
  2. Allergan Inc. $52,955 73 payments
  3. Galderma Laboratories, L.P. $14,621 40 payments
  4. Merz North America, Inc. $10,788 57 payments
  5. Noctrix Health, Inc. $3,492 17 payments
  6. STRATA Skin Sciences, Inc. $2,835 4 payments
  7. Revance Therapeutics, Inc. $1,165 14 payments
  8. Amgen Inc. $482 12 payments
  9. E.R. Squibb & Sons, L.L.C. $282 13 payments
  10. Celgene Corporation $279 4 payments
  11. Other $3,183 136 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $116,562 76 payments
  2. Food and Beverage $17,497 398 payments
  3. Travel and Lodging $9,027 28 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,019 50 payments
  5. Education $182 20 payments
Products named General payments · program years 2019–2025
  1. BOTOX $8,058 50 payments
  2. Xeomin $6,005 31 payments
  3. BOTOX COSMETIC $4,341 8 payments
  4. NIDRA Devices $2,896 15 payments
  5. XTRAC $2,835 4 payments
  6. DAXXIFY $1,165 14 payments
  7. NIDRA Restless Leg Syndrome $596 2 payments
  8. SKYRIZI $528 23 payments
  9. Otezla $482 12 payments
  10. SOTYKTU $282 13 payments
  11. Other $4,666 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $17,029 4 payments
  2. Galderma Laboratories, L.P. $1,800 1 payment
  3. Endo Pharmaceuticals Inc. $200 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Dermatology: 534

Drug cost

$367

Median for Dermatology: $67,151

Branded share of claims

41.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Valacyclovir Valacyclovir Hcl Brand 21 $150
Fluocinonide Generic 13 $111
Doxycycline Hyclate Generic 17 $106

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$11,608

Medicare's payments for the services billed

Medicare patients

80

Average age 75

Services billed

379

62 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 51%
Arthritis 51%
Osteoporosis 28%
Ischemic heart disease 25%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • MERZ NORTH AMERICA, INC. $3,777
$3,777 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $807
$807 — —
BOTOX
  • AbbVie, Inc. $606
$606 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $113
$113 — —
VTAMA
  • Dermavant Sciences, Inc. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

578 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record